New Data Validates Myriad's myRisk Hereditary Breast Cancer Test, Enhanced With riskScore

08 Dec 2017

Results of a 1,617-patient trial, presented at the 2017 San Antonio Breast Cancer Symposium on Dec. 6, show Myriad Genetics' riskScore test, which combines data from the traditional Tyrer-Cuzick model with 86 single nucleotide polymorphisms can predict the five-year and lifetime risk of breast cancer compared to the Tyrer-Cuzick model alone.

Myriad Genetics Inc. says the results of a 1,617-patient validation trial show that its new riskScore breast cancer test, in concert with its myRisk hereditary cancer test, is the most comprehensive breast cancer-risk assessment tool available.

Myriad launched riskScore as a free add-on to myRisk on Sept. 5, but waited until Dec. 7 at the 2017...